Appia Bio
Los Angeles
About Appia Bio
Appia Bio is a biotechnology company that focuses on the research and development of off-the-shelf allogeneic cell therapies. It works on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $52.0M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2021)
- Website: appiabio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/appia-bio-32997 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.